Uncategorized

#ASCO2017 Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143.

Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143. Sub-category: Central Nervous System Tumors Category: Central Nervous System Tumors Meeting: 2017 ASCO Annual Meeting Abstract No: 2001 Citation: J Clin Oncol… Read More ›